Handa Pharmaceuticals, Inc.
6620
Rank in Stocks
#11090
Handa Pharmaceuticals, Inc. operates as a specialized drug company,... Handa Pharmaceuticals, Inc. operates as a specialized drug company, concentrating its efforts on creating and advancing new medications for diverse health issues across both the United States and China. The firm currently offers Quetiapine XR, a treatment for Schizophrenia, as well as Dexlansoprazole DR capsules. Beyond its existing portfolio, Handa is actively cultivating a robust pipeline of therapies. This includes their cutting-edge ONCORE drug delivery platform, engineered to boost patient adherence and improve the safety of tyrosine kinase inhibitor oncology drugs. Other significant projects encompass a 505(b)(2)NDA therapeutic agent, Tascenso ODT for managing multiple sclerosis, and the oncology candidates HND-033 and HND-027. Furthermore, the company's development initiatives feature HND-004, designed for diabetic patients; HND-032, intended to aid in smoking cessation; and HND-026, a gastrointestinal medication. Founded in 2014, Handa Pharmaceuticals, Inc. has its main corporate headquarters situated in Tainan City, Taiwan.
Share Price
$3.75
Last synced: 2026-11-10
Market Cap
$609.42M
Change (1 day)
7.42%
Change (1 year)
-4.09%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Handa Pharmaceuticals, Inc. (6620)
Category
Healthcare
Operating Margin for Handa Pharmaceuticals, Inc. (6620)
Operating Margin as of November 2026 TTM: 37.48%
According to Handa Pharmaceuticals, Inc.'s latest financial reports, its current operating margin (TTM) is 37.48%. At the end of 2025 the company had an operating margin of 54.02%.
Operating Margin history for Handa Pharmaceuticals, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 37.48% | -30.62% |
| 2025 | 54.02% | 7.33% |
| 2024 | 50.33% | -19.70% |
| 2023 | 62.68% | -240.60% |
| 2022 | -44.58% | -94.87% |
| 2021 | -868.42% | -21.06% |
| 2020 | -1,100.10% | 351.29% |
| 2019 | -243.77% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -99.48% |
DE
|
|
| 19.68% | -99.47% |
DE
|
|
| 13.26% | -99.65% |
JP
|
|
| 17.08% | -99.54% |
CH
|
|
| 14.92% | -99.60% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Handa Pharmaceuticals, Inc.'s operating margin
What is Handa Pharmaceuticals, Inc.'s operating margin?
Handa Pharmaceuticals, Inc.'s operating margin is 37.48%, as of Nov 2026.
What was Handa Pharmaceuticals, Inc.'s operating margin in 2025?
In 2025, Handa Pharmaceuticals, Inc.'s operating margin was 54.02%, compared with 50.33% in 2024.
How has Handa Pharmaceuticals, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Handa Pharmaceuticals, Inc.'s operating margin was highest in 2023 (62.68%) and lowest in 2020 (-1,100.10%).
How does Handa Pharmaceuticals, Inc.'s operating margin compare with similar companies?
Handa Pharmaceuticals, Inc.'s operating margin (37.48%) is higher than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.